Parsons Capital Management Inc. RI Has $497,000 Stock Holdings in Kenvue Inc. $KVUE

Parsons Capital Management Inc. RI reduced its stake in Kenvue Inc. (NYSE:KVUE) by 12.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,730 shares of the company’s stock after selling 3,443 shares during the period. Parsons Capital Management Inc. RI’s holdings in Kenvue were worth $497,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of KVUE. Evergreen Wealth Solutions LLC grew its position in Kenvue by 2.6% in the first quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock valued at $402,000 after acquiring an additional 432 shares during the period. Scott & Selber Inc. grew its holdings in shares of Kenvue by 0.4% in the 1st quarter. Scott & Selber Inc. now owns 106,621 shares of the company’s stock worth $2,557,000 after purchasing an additional 475 shares during the last quarter. Wealth Alliance LLC increased its position in shares of Kenvue by 1.6% during the 1st quarter. Wealth Alliance LLC now owns 31,778 shares of the company’s stock worth $762,000 after purchasing an additional 486 shares in the last quarter. Everett Harris & Co. CA increased its position in shares of Kenvue by 1.4% during the 1st quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock worth $887,000 after purchasing an additional 500 shares in the last quarter. Finally, UMB Bank n.a. lifted its holdings in Kenvue by 22.3% during the 2nd quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock valued at $60,000 after purchasing an additional 521 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on KVUE shares. Canaccord Genuity Group decreased their price objective on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Zacks Research raised Kenvue to a “strong sell” rating in a report on Monday, August 11th. UBS Group cut their price objective on Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday, July 17th. Bank of America decreased their target price on Kenvue from $27.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, July 15th. Finally, JPMorgan Chase & Co. cut their price target on Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Friday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $22.46.

Kenvue Stock Up 0.4%

NYSE KVUE opened at $15.80 on Friday. The stock has a market capitalization of $30.31 billion, a P/E ratio of 21.34, a price-to-earnings-growth ratio of 2.26 and a beta of 0.72. Kenvue Inc. has a 52 week low of $15.47 and a 52 week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The stock has a fifty day moving average of $19.71 and a 200-day moving average of $21.58.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 annualized dividend and a dividend yield of 5.3%. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio is presently 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.